Results 61 to 70 of about 2,875 (114)

Variable Aβ tracer uptake in hyperostosis frontalis interna: implications for brain Aβ PET/CT interpretation

Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring
INTRODUCTION Hyperostosis frontalis interna (HFI) is a relatively common incidental finding on head computed tomography (CT). We report two patients with HFI identified on amyloid‐beta (Aβ) positron emission tomography (PET)/CT who demonstrated distinct ...
Joseph M. Ryan, Hina J. Shah, Michael P. McCormick, Alberto Serrano‐Pozo   +3 more
doaj   +1 more source

Donanemab: A comprehensive review of the mechanism, clinical efficacy and safety in early-stage Alzheimer’s disease therapy

Annales Academiae Medicae Silesiensis
Alzheimer’s disease (AD) is a progressive neurodegenerative disease and the main cause of dementia worldwide. It affects cognitive decline, functional impairment and a significant burden on society.
Joanna Ciećwierz, Magdalena Zielińska, Paweł Szajewski, Michał Kotowicz, Aleksandra Zagórska, Maria Koczkodaj, Magdalena Bieniak, Jan Kucharski   +7 more
doaj   +1 more source

“Doctor, if it were you, which would you choose?”: Navigating personal preference questions in anti‐amyloid immunotherapy selection

Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring
The approval of lecanemab and donanemab represents a watershed moment in Alzheimer Disease (AD) treatment, yet clinicians face a novel challenge: guiding patients through treatment selection when head‐to‐head comparative data are absent.
Eric Dinnerstein
doaj   +1 more source

FDA's New Approval: Kisunla (Donanemab-Azbt) - A Major Breakthrough in Alzheimer’s Care

Journal of the Pakistan Medical Association
Madam, Alzheimer’s disease, the most pervasive form of dementia, is a neurodegenerative disorder that relentlessly erodes memory, reasoning and judgment.
Zara Babar, Areesha Babar
doaj   +1 more source

Monoclonal antibodies against beta-amyloid protein (lecanemab and donanemab) should not be used in the treatment of Alzheimer's disease

Arquivos de Neuro-Psiquiatria
Two antiamyloid monoclonal antibodies (mAbs), lecanemab and donanemab, were recently launched for treatment of Alzheimer's disease (AD). These mAbs remove amyloid protein from the brain and cause statistically significant improvement in cognitive ...
Ricardo Nitrini, Adalberto Studart-Neto
doaj   +1 more source

Clinical efficacy of anti‐amyloid antibodies in apolipoprotein E ε4 homozygotes: A Bayesian reanalysis of lecanemab and donanemab phase 3 results

Alzheimer’s & Dementia: Translational Research & Clinical Interventions
INTRODUCTION We aimed to determine the clinical efficacy of treating apolipoprotein E (ApoE) ε4 homozygotes with recently approved anti‐amyloid antibodies. METHODS Data were derived from supplementary analyses in the regulatory studies Clarity (lecanemab)
Stefan Teipel, Yi Tang, Ara Khachaturian
doaj   +1 more source

AAIC 2026 attendance reaches an all‐time high

Alzheimer's &Dementia, Volume 22, Issue 10, October 2026.
wiley   +1 more source

Real-world implementation of lecanemab and donanemab in an Italian memory center: a 1-year experience

Alzheimer’s Research & Therapy
Background Anti-amyloid monoclonal antibodies are entering clinical practice for early symptomatic Alzheimer’s disease (AD), but European real-world data on feasibility, safety, and biomarker monitoring remain limited.
Federica Agosta, Giordano Cecchetti, Edoardo G. Spinelli, Alma Ghirelli, Giulia Rugarli, Stefano Pisano, Federico Coraglia, Elisa Canu, Veronica Castelnovo, Elisa Sibilla, Anna Gilioli, Chiara Tripodi, Fabiola Freri, Alessandra Bianchi, Paolo Vezzulli, Sonia Calloni, Andrea Falini, Ana Maria Samanes Gajate, Andrea Panzacchi, Gino Pepe, Camilla Ferri, Arturo Chiti, Massimo Filippi   +22 more
doaj   +1 more source

Recomendaciones de uso de donanemab

Acta Neurológica Colombiana
La carta al editor presenta recomendaciones actualizadas para el uso de donanemab en la enfermedad de Alzheimer (EA), basadas en su papel dentro de la hipótesis de la cascada amiloide.
Paulina Elizabeth Bombón-Albán, Tatiana Gabriela Aldaz-López   +1 more
doaj   +1 more source

Clinical Meaningfulness of Donanemab in Early Symptomatic Alzheimer Disease: Data From the Randomized Phase 3 TRAILBLAZER-ALZ 2 Trial. [PDF]

Neurol Clin Pract
Atri A, Apostolova LG, Iwata A, Wessels AM, Atkins A, Lu M, Ye W, Ryan S, Doty EG.   +8 more
europepmc   +2 more sources